Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.53 |
| ▸ | F10 | P00742 | 1/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 5/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.50 |
| ▸ | KLK1 | P06870 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.49 |
| ▸ | WNT3A | P56704 | 3/20 | 0.49 |
| ▸ | F12 | P00748 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27673632 | 0.85 | PRMT1 (0.53) | F2F10PRMT1PLGPLAU | |
| SCHEMBL3441414 | 0.81 | AR (0.61) | CTNNB1WNT3AHTR1BIDO1 | |
| SCHEMBL1875949 | 0.78 | IDO1 (0.47) | CTNNB1WNT3AHTR1BIDO1 | |
| SCHEMBL1875948 | 0.78 | IDO1 (0.54) | CTNNB1WNT3AHTR1BIDO1 | |
| SCHEMBL15632598 | 0.77 | CTNNB1 (0.48) | CTNNB1WNT3AHTR1BIDO1 | |
| SCHEMBL16617148 | 0.76 | CTNNB1 (0.54) | CTNNB1WNT3AHTR1BIDO1 | |
| SCHEMBL926708 | 0.75 | DYRK1A (0.48) | F2F10PLGPLAUKLK1 | |
| SCHEMBL29987426 | 0.74 | CTNNB1 (0.63) | CTNNB1WNT3AHTR1BIDO1 | |
| SCHEMBL4318315 | 0.74 | CTNNB1 (0.58) | CTNNB1WNT3AHTR1BIDO1 | |
| SCHEMBL663873 | 0.74 | CTNNB1 (0.63) | CTNNB1WNT3AHTR1BIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1914188-A | Cationic substituted benzofurans as antimicrobial agents | UNIV NORTH CAROLINA (US) | 2007-02-14 | — | — | CN | claimed |
| US-20120035198-A1 | Antiviral Compounds and Methods of Using Thereof | AMAN MOHAMMAD JAVAD (US) | 2012-02-09 | — | — | US | disclosed |
| US-7999001-B2 | Antiviral compounds and methods of using thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2011-08-16 | — | — | US | disclosed |
| US-7994225-B2 | Combination of an antibiotic and a drug such as pentamidine or salts thereof to treat drug resistant eye and ear infections | REMPEX PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7947741-B2 | Use and administration of bacterial efflux pump inhibitors | MPEX PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090012107-A1 | Antiviral Compounds and Methods of Using Thereof | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2009-01-08 | — | — | US | disclosed |
| US-20080132457-A1 | BACTERIAL EFFLUX PUMP INHIBITORS FOR THE TREATMENT OF OPHTHALMIC AND OTIC INFECTIONS | SILICON VALLEY BANK | 2008-06-05 | — | — | US | disclosed |
| CN-1914188-A | Cationic substituted benzofurans as antimicrobial agents | UNIV NORTH CAROLINA (US) | 2007-02-14 | — | — | CN | disclosed |
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-25 | — | — | US | disclosed |
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-25 | — | — | US | disclosed |
| US-20060276473-A1 | Use and administration of bacterial efflux pump inhibitors | REMPEX PHARMACEUTICALS, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7109326-B2 | Halo-alkoxycarbonyl prodrugs | GENENTECH, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-0975608-B1 | HALO-ALKOXYCARBONYL PRODRUGS | GENENTECH INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040220401-A1 | Novel halo-alkoxycarbonyl prodrugs | GENENTECH, INC. | 2004-11-04 | — | — | US | disclosed |
| US-20010020019-A1 | NOVEL HALO-ALKOXYCARBONYL PRODRUGS | GENENTECH, INC. | 2001-09-06 | — | — | US | disclosed |
| EP-0975608-A2 | HALO-ALKOXYCARBONYL PRODRUGS | Genentech, Inc. (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046576-A2 | HALO-ALKOXYCARBONYL PRODRUGS | GENENTECH, INC. (US) | 1998-10-22 | — | — | WO | disclosed |
| US-4619942-A | Inhibition of Respiratory Syncytial virus-induced cell fusion by amidino compounds | UNIVERSITY OF NORTH CAROLINA (US) | 1986-10-28 | — | — | US | disclosed |
| US-4397863-A | PROPHYLAXIS | RESEARCH TRIANGLE INSTITUTE (US) | 1983-08-09 | — | — | US | disclosed |
| US-4324794-A | PREVENTION OF EPIDEMICS BY PROPHYLACTIC ADMINISTRATION | RESEARCH TRIANGLE INSTITUTE (US) | 1982-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012107-A1 | Antiviral Compounds and Methods of Using Thereof | ZC3HAV1, MAVS, ZC3HAV1L | F2 4102/4885F10 3465/4885PRMT1 1610/4885 |
| US-20040220401-A1 | Novel halo-alkoxycarbonyl prodrugs | PNP, PAICS, PHOSPHO1 | F2 4407/4885F10 4252/4885PRMT1 3743/4885 |
| US-20060276473-A1 | Use and administration of bacterial efflux pump inhibitors | ABCB11, ABCC1, ABCB1 | F2 4870/4885F10 4613/4885PRMT1 4111/4885 |
| US-20120035198-A1 | Antiviral Compounds and Methods of Using Thereof | ZC3HAV1, MAVS, ZC3HAV1L | F2 4102/4885F10 3465/4885PRMT1 1610/4885 |
| US-20080132457-A1 | BACTERIAL EFFLUX PUMP INHIBITORS FOR THE TREATMENT OF OPHTHALMIC AND OTIC INFECTIONS | ABCB11, SLC47A2, SLC47A1 | F2 4843/4885F10 3948/4885PRMT1 4691/4885 |
| US-20010020019-A1 | NOVEL HALO-ALKOXYCARBONYL PRODRUGS | PNP, PAICS, PHOSPHO1 | F2 4407/4885F10 4252/4885PRMT1 3743/4885 |
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | APP, IAPP, GRN | F2 3712/4885F10 2178/4885PRMT1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.